000			02249 a2200565 4500
005			20250516223703.0
264		0	_c20150224
008			201502s 0 0 eng d
022			_a1178-2005
024	7		_a10.2147/COPD.S62502 _2doi
040			_aNLM _beng _cNLM
100	1		_aKoch, Andrea
245	0	0	_aLung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. _h[electronic resource]
260			_bInternational journal of chronic obstructive pulmonary disease _c2014
300			_a697-714 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Inhalation
650	0	4	_aAdrenergic beta-2 Receptor Agonists _xadministration & dosage
650	0	4	_aAged
650	0	4	_aArea Under Curve
650	0	4	_aBenzoxazines _xadministration & dosage
650	0	4	_aBronchodilator Agents _xadministration & dosage
650	0	4	_aDrug Administration Schedule
650	0	4	_aEquipment Design
650	0	4	_aEthanolamines _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aForced Expiratory Volume
650	0	4	_aFormoterol Fumarate
650	0	4	_aHumans
650	0	4	_aLung _xdrug effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNebulizers and Vaporizers
650	0	4	_aPredictive Value of Tests
650	0	4	_aPulmonary Disease, Chronic Obstructive _xdiagnosis
650	0	4	_aRecovery of Function
650	0	4	_aRespiratory Function Tests
650	0	4	_aSeverity of Illness Index
650	0	4	_aSurveys and Questionnaires
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aPizzichini, Emilio
700	1		_aHamilton, Alan
700	1		_aHart, Lorna
700	1		_aKorducki, Lawrence
700	1		_aDe Salvo, Maria Cristina
700	1		_aPaggiaro, Pierluigi
773	0		_tInternational journal of chronic obstructive pulmonary disease _gvol. 9 _gp. 697-714
856	4	0	_uhttps://doi.org/10.2147/COPD.S62502 _zAvailable from publisher's website
999			_c24026774 _d24026774